Tradestie Institutional Equity Comparison Engine

REPL vs EVMN โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

EVMN Overall Edge

EVMN Captures Institutional Edge (2โ€“1 Pillars ยท 2โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Evommune, Inc. (EVMN) driven by superior Growth & Margin, Options & Structure while REPL counters with relative strength in Momentum & Technical. Fundamentally, REPL trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus EVMN at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, REPL sits in BREAKOUT (23rd %ile IV; Dealer Gamma Walls on Pro) against EVMN sits in SURGE (53rd %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
REPL N/M vs EVMN N/M Fwd P/E
Growth & Margin Winner EVMN
Op Margin 0.0% vs 0.0% ยท YoY +0.0% vs +0.0%
Momentum & Technical Winner REPL
1Y +136.8% vs -61.0% ยท 52W Pos 90% vs 8%
Options & Structure Winner EVMN
BREAKOUT (23rd %ile IV) vs SURGE (53rd %ile IV)
REPL NASDAQ
Replimune Group, Inc.
Biological Products, (No Disgnostic Substances)
$21.41
-2.19% 1D
Market Cap $2.1B
1M Return +97.15%
1Y Return +136.84%
Forward P/E N/M
Unified AI Score
27.4 / 100 SELL
Tech 50.0 Fund 34.0 Flow 67.0 Mom 50.0
EVMN US Equity
Evommune, Inc.
Pharmaceutical Preparations
$7.10
-6.95% 1D
Market Cap $315.5M
1M Return +37.33%
1Y Return -61.03%
Forward P/E N/M
Unified AI Score
30.0 / 100 SELL
Tech 50.0 Fund 35.0 Flow 69.0 Mom 44.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: REPL +136.84% EVMN -61.03% Spread: +199.45 pp (REPL Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
REPL TTM Op. Margin: 0.0% EVMN TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on REPL vs EVMN. Trailing 12-month operating profitability (REPL 0.0% vs EVMN 0.0%) and valuation multiples (REPL N/M vs EVMN N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: REPL (3) vs EVMN (2)
Institutional Metric REPL EVMN Criterion Row Winner
Market Capitalization Scale $2.1B $315.5M Larger Scale REPL
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +0.0% +0.0% Higher Growth Tie
Operating Margin (TTM) Profitability 0.0% 0.0% Higher Margin Tie
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -115.8% -69.5% Higher ROE EVMN
52-Week Range Position Momentum 90% ($2โ€“$24) 8% ($5โ€“$33) Stronger Trend REPL
Beta / 30D Volatility Risk Regime 2.08ฮฒ ยท 100% Vol 1.05ฮฒ ยท 118% Vol Lower Realized Risk REPL
Unified Institutional Score Composite Signal 27.4 / 100 (SELL) 30.0 / 100 (SELL) Higher Composite EVMN

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full REPL vs EVMN Buy Guide
REPL BREAKOUT
98d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 23rd %ile
IV Regime Compressed (<25th %ile)
Live REPL Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
EVMN SURGE
5d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 53rd %ile
IV Regime Balanced (25thโ€“60th %ile)
Live EVMN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither REPL nor EVMN registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.